CordenPharma & GENEPEP Celebrate Strong Collaboration Leveraging Peptide Drug Substance Discovery & Clinical Development Expertise

CordenPharma and GENEPEP have recently celebrated 1 year of their fruitful partnership signed in 2023, which supports biotech companies with the development, discovery, and manufacturing of peptides for early clinical phase, leveraging CordenPharma’s cGMP manufacturing capacities, regulatory know-how, and market access, as well as GENEPEP’s discovery and drug development expertise. Under the terms of the agreement, GENEPEP provides services for research and discovery activities, as well as support for initial Investigational New Drug (IND) application packages, including selection of lead and alternative compounds for discovery purpose, research-grade samples including testing reports, process familiarization, and development.

In addition, they supply gram peptide manufacturing samples representative of tox quality, ensuring a smooth and seamless transition to the CordenPharma Frankfurt site for early clinical GMP manufacturing, along with access to their global sales and marketing organization.

Dr. Stéphane Varray, CordenPharma’s Global Peptide Platform Director, said “With our new early clinical GMP peptide manufacturing investment in Frankfurt and the strategic partnership with GENEPEP, we are proud to strengthen our peptide offering for biotech and pharma customers in early discovery to First-In-Human clinical stage. In the past 12 months, we have demonstrated together how this collaboration has simplified and expedited the critical milestones of lead development and validation in a clinical setting, bringing added value for our global customers.”

Dr. Karine Puget, founder and CEO of GENEPEP, added “Thanks to this collaboration between GENEPEP & CordenPharma, customers of both companies now have access to collaborative and specialized teams tailored to meet the needs of each of the Research and Development phases of their project.”

CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.

With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).

The CordenPharma Group is composed of 11 facilities across Europe and North America. In the 2023 financial year, the organization generated sales of 890 million Euros and had over 3,000 employees. For more information, visit cordenpharma.com.

GENEPEP SAS is French CRO company founded in 2003 and dedicated to peptide synthesis for early-stage project (non GMP). After more than 20 years of existence, the company has solid experience in chemical production of all kinds of peptides with more than 23,000 successfully synthesized compounds to its credit, 16 scientific publications & 3 patents. GENEPEP invested in its own R&D; works in « green chemistry » and has developed PFAs free method. Agility, high quality, innovative chemical processes, short delivery times and competitive prices characterize the company. For more information, visit genepep.com.